HOME >> MEDICINE >> NEWS
New drug shows promise for saving lives from heart failure

ATLANTA, Nov. 10 -- A new drug for heart failure saves lives and reduces symptoms, according to a study presented today at the American Heart Association Scientific Sessions.

The new drug, called omapatrilat, is a member of a new class of compounds called vasopeptidase inhibitors.

The results of this study, combined with others, suggest that the use of omapatrilat may reduce deaths and hospitalizations from congestive heart failure by as much as 30 percent, says Jean-Lucien Rouleau, M.D., director of cardiology, Mount Sinai Hospital Association at the University Health Network of Toronto, Canada. "It's a potential breakthrough in the treatment of congestive heart failure."

Congestive heart failure is a condition in which the heart can't pump enough blood to meet the needs of other organs in the body. It occurs in hearts that are damaged or overworked after a heart attack, high blood pressure, heart valve disease, congenital defects or infection of the heart or its valves. Drugs used to treat heart failure include digitalis, which increases the heart's pumping action; diuretics, which help eliminate the buildup of fluid in the body's tissues; and vasodilators, which expand blood vessels, allowing blood to flow more easily and making the heart's work easier and more efficient.

Among the vasodilators is a class of drugs know as angiotensin converting enzyme (ACE) inhibitors, which interfere with the body's production of angiotensin, a chemical that causes arteries to constrict.

The problem with ACE inhibitors, according to Rouleau, is that they do not work on all substances in the body that promote abnormal constriction of arteries, which is characteristic of heart failure.

The new drug works in two ways. Like conventional ACE inhibitors, it blocks the action of angiotensin, inhibiting the constrictive action of this substance. But omapatrilat also neutralizes a substance called neutral endopeptidase, resulting in blood vessels rel
'"/>

Contact: Carole Bullock
caroleb@heart.org
214-706-1279
American Heart Association
9-Nov-1999


Page: 1 2 3

Related medicine news :

1. Study shows promise in identifying kidney failure
2. Study shows patch therapy may be as effective as oral medications
3. Study shows soy is well accepted in school lunches
4. Chronic pain treatments more effective when taken together, new study shows
5. UW study shows blacks and Latinos are more satisfied with physicians of the same race
6. Vaccine against childhood pneumonia shows promise
7. UW research shows risk factors for relapse among health care professionals who abuse drugs
8. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
9. New technique shows promise for improved straightening of crooked nose
10. Chemical decoy shows promise for slowing Alzheimers by acting as decoy
11. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... December 07, 2016 , ... Augustine Insurance Agency, a ... and business owners in the greater Dallas metropolitan area, is announcing a charity ... Foundation. , Established in 2009 by active police professionals in the Dallas region, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the nationally ... Your Health on Voice of America, declared on her radio program in November 2016 ... fact that when these bullies attack leaders in corporate America, they are trying to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live From won ... year’s best in pioneering, inventive, and ultimately successful projects undertaken by the media ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, LA.c., ... Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of experience ... to help patients realize their family building goals. Acupuncture helps fertility patients ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma Alliance ( ... cavernous angiomas, was awarded a grant from the Julian Grace Foundation to increase ... has more people with cavernous angioma than anywhere in the world. Most share ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  Alopexx Oncology, LLC ... a recombinant antibody fusion protein (immunocytokine) composed of interleukin-2 ... the same target on B cells as Rituxan and ... components but is also involved in tumor targeting, engagement ... vaccine effect. The results of the study (abstract #95954) ...
(Date:12/6/2016)... 2016 Homozygous Familial Hypercholesterolemia (HoFH) ... Global Markets Direct,s latest Pharmaceutical and ... (HoFH) – Pipeline Review, H2 2016, provides ... (HoFH) (Metabolic Disorders) pipeline landscape. Homozygous ... is caused due to mutation from both ...
(Date:12/6/2016)... CENTENNIAL, Colo. , Dec. 6, 2016 /PRNewswire-USNewswire/ ... providers of cartilage, cellular, bone, skin and soft-tissue ... Kimberly Meyer , Business Process Manager, for being ... 2016 Malcolm Baldrige National Quality Award by the ... (NIST), deepening the organization,s commitment to process excellence. ...
Breaking Medicine Technology:
Cached News: